S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The single greatest medical breakthrough of all time? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The single greatest medical breakthrough of all time? (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
The single greatest medical breakthrough of all time? (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:BTTX

Better Therapeutics (BTTX) Stock Forecast, Price & News

$0.73
0.00 (0.00%)
(As of 06/5/2023 ET)
Compare
Today's Range
$0.70
$0.78
50-Day Range
$0.64
$1.46
52-Week Range
$0.59
$2.80
Volume
185,297 shs
Average Volume
185,051 shs
Market Capitalization
$23.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Better Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
858.9% Upside
$7.00 Price Target
Short Interest
Healthy
4.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$447,794 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.33) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

572nd out of 985 stocks

Health Services Industry

8th out of 13 stocks


BTTX stock logo

About Better Therapeutics (NASDAQ:BTTX) Stock

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Receive BTTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTTX Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Chardan Capital Remains a Buy on Better Therapeutics, Inc. (BTTX)
Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
A Preview Of Better Therapeutics's Earnings
See More Headlines

BTTX Price History

BTTX Company Calendar

Today
6/06/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Health services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTTX
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+858.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-39,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
($0.04) per share

Miscellaneous

Free Float
12,883,000
Market Cap
$23.16 million
Optionable
Not Optionable
Beta
1.57

Key Executives

  • Mr. David P. Perry M.B.A. (Age 55)
    Co-Founder & Exec. Chairman
    Comp: $194.71k
  • Dr. Mark A. Berman M.D. (Age 48)
    Chief Medical Officer
    Comp: $576.38k
  • Ms. Kristin Wynholds (Age 51)
    Chief Product Officer
    Comp: $586.5k
  • Mr. Frank L. Karbe (Age 55)
    CEO, Pres & Director
  • Mr. Mark HeinenMr. Mark Heinen (Age 54)
    Head of Fin. & Interim CFO
  • Mr. Andres Camacho
    Sr. VP of Technology & Head of Engineering
  • Mr. Thiago Licias De Oliveira
    Chief People Officer
  • Ms. Diane Gomez-Thinnes
    Chief Commercial Officer













BTTX Stock - Frequently Asked Questions

Should I buy or sell Better Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Better Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTTX shares.
View BTTX analyst ratings
or view top-rated stocks.

What is Better Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 1-year price objectives for Better Therapeutics' stock. Their BTTX share price forecasts range from $5.00 to $9.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 858.9% from the stock's current price.
View analysts price targets for BTTX
or view top-rated stocks among Wall Street analysts.

How have BTTX shares performed in 2023?

Better Therapeutics' stock was trading at $1.1050 on January 1st, 2023. Since then, BTTX shares have decreased by 33.9% and is now trading at $0.73.
View the best growth stocks for 2023 here
.

Are investors shorting Better Therapeutics?

Better Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 154,600 shares, an increase of 19.1% from the April 30th total of 129,800 shares. Based on an average daily volume of 128,100 shares, the short-interest ratio is presently 1.2 days. Approximately 4.8% of the company's shares are sold short.
View Better Therapeutics' Short Interest
.

When is Better Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BTTX earnings forecast
.

What is Better Therapeutics' stock symbol?

Better Therapeutics trades on the NASDAQ under the ticker symbol "BTTX."

Who are Better Therapeutics' major shareholders?

Better Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (2.93%). Insiders that own company stock include Andrew J Armanino, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark Heinen and Risa J Lavizzo-Mourey.
View institutional ownership trends
.

How do I buy shares of Better Therapeutics?

Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Better Therapeutics' stock price today?

One share of BTTX stock can currently be purchased for approximately $0.73.

How much money does Better Therapeutics make?

Better Therapeutics (NASDAQ:BTTX) has a market capitalization of $23.16 million and generates $10,000.00 in revenue each year. The company earns $-39,760,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How can I contact Better Therapeutics?

Better Therapeutics' mailing address is 311 WEST 43RD STREET 12TH FLOOR, NEW YORK NY, 10036. The official website for the company is mcacquisition.com. The company can be reached via phone at 415-887-2311 or via email at mcac@icrinc.com.

This page (NASDAQ:BTTX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -